Gujarat Themis Biosyn Shows Improved Technical Trend Amid Mixed Financial Performance
Gujarat Themis Biosyn, a small-cap pharmaceutical company, has recently experienced a score adjustment reflecting a shift to a mildly bullish trend. The firm boasts a high return on equity and a low debt-to-equity ratio, although it has encountered challenges with flat financial performance and declining profits in the past year.
Gujarat Themis Biosyn, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment. This revision in its score reflects a shift in the technical trend from a sideways movement to a mildly bullish stance. The stock has demonstrated notable performance indicators, including a high return on equity (ROE) of 42.39%, indicating strong management efficiency. Additionally, the company maintains a low debt-to-equity ratio, which is favorable for its financial health. Over the past year, Gujarat Themis Biosyn has outperformed the BSE 500 index, achieving a return of 27.75%.
Despite these positive aspects, the company has faced challenges, including flat financial performance in the latest quarter and a decline in profits over the past year. The net sales growth rate has been modest at 12.12% annually over the last five years, while operating profit growth stands at 15.81%.
Overall, the stock's technical indicators, such as MACD and Bollinger Bands, suggest a bullish sentiment, while the company's valuation remains on the higher side compared to its peers.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
